Evaluation of the efficacy, safety, and economy of nemonoxacin injection versus moxifloxacin injection in the treatment of community-acquired pneumonia.

Front Pharmacol · 2026 · PMC13167417 · PMID 42137337

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not reach statistical significanceP = 0.052so close (0.05 < p ≤ 0.1)

Although the difference in post-treatment C-reactive protein (CRP) levels between the two groups did not reach statistical significance ( P = 0.052), the numerical difference (7.71 mg/L in the nemonoxacin group vs. 18.80 mg/L in the moxifloxacin group) is clinically noteworthy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.